Advanced glycosylation end products (AGEs), insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) in patients with Type 2 diabetes mellitus

Diabetes/Metabolism Research and Reviews

Volumn 16, Issue 2, 2000, Pages 106-113

  Garay Sevilla, Ma Eugenia ^a   Nava, Laura Eugenia ^a   Malacara, Juan Manuel ^a   Wróbel, Kazimierz ^b   Wróbel, Katarzyna ^b   Pérez, Ulises ^a  

^a UNIVERSITY OF GUANAJUATO   (Mexico)

^b Inst de Invest Científicas   (Mexico)

Author keywords

Advanced glycosylation end products; Complications of diabetes; Diabetes mellitus; Diabetic nephropathy; Free IGF 1; IGFBP 3

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HEMOGLOBIN A1C; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; COMMUNICABLE DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INPATIENTS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; REFERENCE VALUES; REGRESSION ANALYSIS;

EID: 0034050943     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-7560(200003/04)16:2<106::AID-DMRR88>3.0.CO;2-H     Document Type: Article

References (41)

1. Cerami A, Vlassara H, Brownlee M. Glucose and aging. Sci Am 1987; 256(5): 90-96.
2. Brownlee M, Cerami A, Vlassara H. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984; 101: 527-537.
3. Ruderman N, Williamson J, Brownlee M. Glucose and diabetic vascular disease. FASEB J 1992; 6: 2905-2914.
4. Belmin J, Valensi P. Diabetic neuropathy in elderly patients. What can be done? Drugs Aging 1996; 8: 416-429.
5. Wu JT. Advanced glycosylation end products: a new disease marker for diabetes an aging. J Clin Lab Anal 1993; 7: 252-255.
6. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997; 42: 519-525.
7. Li YM, Tan AX, Vlassara H. Antibacterial activity of lysozyme and lactoferrin is inhibiting by binding of advanced glycation-modified proteins to a conserved motif. Nat Med 1995; 1: 1057-1061.
8. Makita Z, Vlassara H, Cerami A, Bucala R. Inmunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992; 267: 5133-5138.
9. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325(12): 836-842.
10. Wróbel ZK, Wróbel K, Garay SME, Nava LE, Malacara JM. A novel approach to monitoring the advanced glycosylation end products (AGEs) in human serum using on-line spectrophotometric and spectrofluorimetric detection in flow system. Clin Chem 1997; 43: 1563-1569.
11. Li YM, Tan AX, Vlassara H. Antibacterial activity of lysosyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat Med 1995; 1: 1057-1061.
12. Grant M, King GL. IGF-1 and blood vessels - implications for microvascular and macrovascular disease. Diabetes Metab Rev 1995; 3(1): 113-128.
13. Lee PDK, Conover CA, Powel DR. Regulation and function of insulin-like growth factor-binding protein-1 [mini review]. Proc Soc Exp Biol Med 1993; 204: 4-29.
14. Janssen J, Jacobs ML, Derkx FHM, Weber RFA, Van Der Lely AJ, Lamberts SWJ. Free and total insulin-like growth factor 1 (IGF-1), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in Type 1 diabetes. J Clin Endocrinol Metab 1997; 82: 2809-2815.
15. Feldmann B, Lang GE, Arnavaz A, Jehle PM, Byoam BO, Lang GK. Decreased serum level of free bioavailable IGF-1 in patients with diabetic retinopathy. Ophthalmologe 1999; 96(5): 300-305.
16. Rechler MM. Insulin-like growth factor binding proteins. Vitam Horm 1993; 47: 1-114.
17. Baxter RC, Martin JL. Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog Growth Factors Res 1989; 1: 49-68.
18. Ross M, Francis GL, Szabo L, Wallance JC, Ballard FJ. Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. Biochem J 1989; 258: 267-272..
19. Sara VR, Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev 1990; 70: 591-614.
20. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997; 18: 801-831.
21. Gibson JM, Wetswood M, Young RJ, White A. Reduced insulin-like growth factor binding protein-1 (IGFBP-3) levels correlate with increased cardiovascular risk in Type 2 diabetes. J Clin Endocrinol Metab 1996; 81: 860-863.
22. Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 1995; 26: 875-888.
23. Merimee TJ, Fineberg SE, McKusick VA, Hall JC. Diabetes mellitus and sexual ateliotic dwarfism. J Clin Invest 1970; 49: 1096-1102.
24. Merimee TJ. Metabolic and clinical studies in growth hormone deficient dwarfs: a ten year follow-up. N Engl J Med 1978; 298: 1217-1222.
25. American Diabetes Association. Office Guide to diagnosis and classification of diabetes mellitus and other categories of glucose intolerance. Diabetes Care 1996; 19(supplement): S4.
26. Bucala R, Cerami A, Vlassara H. Advanced glycosylation end products in diabetic complications. Diabetes Metab Rev 1995; 3: 258-268.
27. Karbet SM, Makita Z, Firanek CA, Vlasara H. Advanced glycolysation end products in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993; 22: 588-591.
28. Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors: Studies in diabetics with and without retinopathy. N Engl J Med 1983; 309: 527-530.
29. Dills DG, Moss SE, Klein R, Klein BE, Davis M. Is insulin-like growth factor associated with diabetic retinopathy? Diabetes 1990; 9: 191-195.
30. Sÿonksen PH, Russell-Jones RH. Growth hormone and diabetes mellitus. Horm Res 1993; 40: 68-79.
31. Tamborlane WV, Hintz RL, Berman M, Genel M, Felig P, Sherwin RS. Insulin-infusion-pump treatment of diabetes: influence of improved metabolic control on plasma somatomedin levels. N Engl J Med 1981; 305: 303-307.
32. Kristein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor in human monocytes by advanced glycosilation end product-modified proteins. J Clin Invest 1992; 90: 439-446.
33. Jorgensen JO, Blum WF, Moller N, Ranke MB, Christiansen SJ. Short-term changes in insulin-like growth factors (IGF) and IGF binding protein 3 after different modes of intravenous growth hormone (GH) exposer in GH deficient patients. J Clin Endocrinol Metab 1991; 72: 582-587.
34. Davies SC, Wass JAH, Ross RJM, et al. Induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation of severe illness. J Endocrinol 1991; 130: 469-473.
35. Batch JA, Baxter RC, Werther GA. Abnormal regulation of insulin-like growth factor binding proteins in adolescents with Type 1 diabetes. J Clin Endocrinol Metab 1991; 73: 964-968.
36. Donahue LR, Hunter SJ, Sherblom AP, Rosen CJ. Age related changes in serum insulin-like growth factor biding proteins in women. J Clin Endocrinol Metab 1990; 71: 575-579.
37. Rasmussen MH, Frystyk J, Anderson T, Breum L, Christiansen JS, Hilsted J. The impact of obesity, fat distribution, and energy restriction on insulin-like growth factor-1 (IGF-1), IGF binding protein-3, insulin, and growth hormone. Metabolism 1994; 43: 315-319.
38. Bereket A, Lang CH, Blethen SL, Fan J, Frost RA, Wilson TA. Insulin-like growth factor binding protein-3 proteolysis in children with Type 1 diabetes: a possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 1995; 80: 2282-2288.
39. Mohan S. Insulin-like growth factor binding protein in bone cell regulation. Growth Regul 1993; 3: 67-70.
40. Johansson AG, Forslund A, Hambreaus L, Blum WF, Lunghal S. Growth hormone-dependent insulin like growth factor binding protein is a major determinant of bone mineral density in healthy men. J Bone Miner Res 1994; 9: 915-921.
41. Tonsoff B, Blum WF, Mehls O. Serum insulin-like growth factors and their binding proteins in children with end-stage renal disease. Pediatr Nephrol 1996; 10: 269-274.